 Connection
Vanessa Fabrizio to Recurrence
This is a "connection" page, showing publications Vanessa Fabrizio has written about Recurrence.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.396 |
|
|
|
-
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):1961-1968.
Score: 0.140
-
Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 01 25; 6(2):600-610.
Score: 0.138
-
Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes B, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi AA, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS, De Moerloose B, Dickens DS, Duffner U, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari Z, Grupp SA, He RR, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay T, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost M, Puri L, Raikar SS, Martinez A, Bristol I, Murphy K, Reiman L, Redell M, Reed K, Roth-Guepin G, Rubinstein J, Savasan S, Schafernak K, Stevens A, Talleur A, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ, Shah NN. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025 Jul 24; 146(4):437-455.
Score: 0.044
-
Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 02 28; 7(4):541-548.
Score: 0.037
-
Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 01 10; 41(2):354-363.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|